Definitive or palliative treatment: case report of cancer breast survivor with ovarian mass
DOI:
https://doi.org/10.18203/2349-2902.isj20230997Keywords:
Metachronous ovarian cancer, Breast metastasis, Secondary tumour, Carcinoma breast, Case reportAbstract
Cancers survivors with second tumour mass. The difficult thing in these situations is definitive diagnosis. One sentence which shapes the future of a patient-a steep see saw of definitive and palliative treatment. What saves the clinician in this scenario is the immunohistochemistry (IHC). It single handedly brightens the path and leads to conclusion. This case report demonstrated the same in breast cancer survivor.
References
Zaaijer LH, van Doorn HC, Mourits MJ. Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers. Brit J Cancer. 2016;115(10):1174-8.
He XQ, Gao YT, Zhang X, Jiang H. Time intervals between double primary breast and ovarian cancers and survival outcomes of patients with both cancers: a SEER database analysis. Biomed Res Int. 2022;2022:4557346.
Tasca G, Dieci MV, Baretta Z, Faggioni G, Montagna M, Nicoletto MO, et al. Synchronous and metachronous breast and ovarian cancer: experience from two large cancer center. Front Oncol. 2020;10:608783.
Painter JT, Clayton NP, Herbert RA. Useful immunohistochemical markers of tumor differentiation. Toxicol Pathol. 2010;38(1):131-41.
Kriplani D, Patel MM. Immunohistochemistry: A diagnostic aid in differentiating primary epithelial ovarian tumors and tumors metastatic to the ovary. South Asian J Cancer. 2013;2(4):254-8.